MASH is short for metabolic dysfunction–associated steatohepatitis.
Fatty liver is an excess of fat buildup in the liver. This can damage the liver, potentially becoming a serious form of fatty liver disease called MASH. A number of negative health consequences, including liver scarring, may occur as the liver reacts to these changes.
As MASH progresses, liver scarring can increase. There can be no symptoms, and even when there are symptoms, they may not clearly point to MASH.
If unaddressed, MASH can increase the risk of both liver failure and liver cancer. MASH is also associated with heart disease. However, when caught as soon as possible, MASH can be managed with lifestyle changes and improved with treatment.
NASH is nonalcoholic steatohepatitis. It was recently renamed MASH, or metabolic dysfunction–associated steatohepatitis, to better reflect the metabolic nature of this liver disease.
MASH is largely caused by metabolic dysfunction. This means the body’s processing and distributing of specific nutrients, like fats or carbohydrates, is altered.
Certain conditions are associated with an increased risk for MASH. If you are living with any of the conditions below, talk to your health care professional about your personal risk for MASH with liver scarring.
HDL, high-density lipoprotein.
There are noninvasive testing options to detect MASH and assess the risk of liver scarring. MASH can progress or worsen over time, so you and your health care professional will work together to create a comprehensive MASH management plan.
Actor portrayals.
Wegovy® may cause serious side effects, including:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy® may affect the way some medicines work and some medicines may affect the way Wegovy® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy® slows stomach emptying and can affect medicines that need to pass through the stomach quickly.
Wegovy® may cause serious side effects, including:
The most common side effects of Wegovy® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat.
Please see Prescribing Information and Medication Guide for Wegovy®.
Wegovy® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
This site is intended for US patients only.
WEGOVY® (semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.
This indication is approved based on improvement of MASH and liver scarring (fibrosis). There is an ongoing study to confirm the clinical benefit of Wegovy® in adults with MASH.
Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.
It is not known if Wegovy® is safe and effective for use for the treatment of MASH in children under 18 years.
WEGOVY® (semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.
This indication is approved based on improvement of MASH and liver scarring (fibrosis). There is an ongoing study to confirm the clinical benefit of Wegovy® in adults with MASH.
Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.
It is not known if Wegovy® is safe and effective for use for the treatment of MASH in children under 18 years.
Wegovy® may cause serious side effects, including:
Wegovy® may cause serious side effects, including:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy® may affect the way some medicines work and some medicines may affect the way Wegovy® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy® slows stomach emptying and can affect medicines that need to pass through the stomach quickly.
Wegovy® may cause serious side effects, including:
The most common side effects of Wegovy® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat.
Please see Prescribing Information and Medication Guide for Wegovy®.
Wegovy® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
This site is intended for US patients only.
WEGOVY® (semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.
This indication is approved based on improvement of MASH and liver scarring (fibrosis). There is an ongoing study to confirm the clinical benefit of Wegovy® in adults with MASH.
Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.
It is not known if Wegovy® is safe and effective for use for the treatment of MASH in children under 18 years.